peptide-solutions
Cagrilintide + semaglutide combination preparation (10 mg per vial)
Research Compound
Manufactured under strict quality control protocols with full analytical testing. Certificate of Analysis (COA) available upon request.

A combination preparation of cagrilintide (long-acting amylin analog) and semaglutide (GLP-1 receptor agonist) at a 1:1 ratio. Research explores complementary effects on appetite regulation, satiety signaling, and body composition.
Compound Specifications
Select the amount contained in each vial.
Choose one vial, or choose a kit with 10 units priced as 8.
Amount per vial: 10mg
Scientific Documentation
Detailed research information, pharmacological profile, and handling specifications
Cagrilintide engages amylin and calcitonin receptors to slow gastric emptying and signal satiety; semaglutide activates GLP-1R for glucose-dependent insulin secretion and appetite suppression. The combination targets parallel satiety pathways.
Verified Buyer Reviews
Loading reviews...
This product is intended strictly for laboratory and research purposes only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm that you are an authorized researcher or institution and that this product will be used solely for legitimate research purposes in compliance with all applicable laws and regulations.
Other research peptides you may be interested in

GLP-1 receptor agonist for metabolic research
from $83

Triple-action GLP-1/GIP/Glucagon receptor agonist
from $125

Dual GLP-1/GIP receptor agonist for metabolic research
from $109